image stringlengths 20 66 | question stringclasses 16
values | answer stringlengths 3 10.7k |
|---|---|---|
PMC2359968_fig1_20959.jpg | Can you identify the primary element in this image? | Immunohistochemical and immunofluorescence staining with L19-SIP antibody in SW1222 and LS174T xenograft-bearing mice. (A) Immunohistochemical staining of SW1222 xenograft lines with L19-SIP antibody. (B–D) Multiple digital fluorescence images of an LS174T tumour injected with Cy3-labelled L19-SIP antibody for 6 h demo... |
PMC2359968_fig1_20960.jpg | What can you see in this picture? | Immunohistochemical and immunofluorescence staining with L19-SIP antibody in SW1222 and LS174T xenograft-bearing mice. (A) Immunohistochemical staining of SW1222 xenograft lines with L19-SIP antibody. (B–D) Multiple digital fluorescence images of an LS174T tumour injected with Cy3-labelled L19-SIP antibody for 6 h demo... |
PMC2359968_fig1_20958.jpg | What object or scene is depicted here? | Immunohistochemical and immunofluorescence staining with L19-SIP antibody in SW1222 and LS174T xenograft-bearing mice. (A) Immunohistochemical staining of SW1222 xenograft lines with L19-SIP antibody. (B–D) Multiple digital fluorescence images of an LS174T tumour injected with Cy3-labelled L19-SIP antibody for 6 h demo... |
PMC2359968_fig1_20957.jpg | What is shown in this image? | Immunohistochemical and immunofluorescence staining with L19-SIP antibody in SW1222 and LS174T xenograft-bearing mice. (A) Immunohistochemical staining of SW1222 xenograft lines with L19-SIP antibody. (B–D) Multiple digital fluorescence images of an LS174T tumour injected with Cy3-labelled L19-SIP antibody for 6 h demo... |
PMC2359978_fig4_20974.jpg | What stands out most in this visual? | Expression of p16 protein detected by immunohistochemistry. Immunohistochemistry was performed on frozen primary ESFT (n=37) and p16 protein detected using the CSA System. Tumours were negative (A), expressed in focal hotspots (B) or throughout the tumour (C). Homozygous deletion of CDKN2A correlated with loss of p16 p... |
PMC2359978_fig4_20971.jpg | What is the main focus of this visual representation? | Expression of p16 protein detected by immunohistochemistry. Immunohistochemistry was performed on frozen primary ESFT (n=37) and p16 protein detected using the CSA System. Tumours were negative (A), expressed in focal hotspots (B) or throughout the tumour (C). Homozygous deletion of CDKN2A correlated with loss of p16 p... |
PMC2359978_fig4_20972.jpg | What is the main focus of this visual representation? | Expression of p16 protein detected by immunohistochemistry. Immunohistochemistry was performed on frozen primary ESFT (n=37) and p16 protein detected using the CSA System. Tumours were negative (A), expressed in focal hotspots (B) or throughout the tumour (C). Homozygous deletion of CDKN2A correlated with loss of p16 p... |
PMC2359978_fig4_20973.jpg | What is shown in this image? | Expression of p16 protein detected by immunohistochemistry. Immunohistochemistry was performed on frozen primary ESFT (n=37) and p16 protein detected using the CSA System. Tumours were negative (A), expressed in focal hotspots (B) or throughout the tumour (C). Homozygous deletion of CDKN2A correlated with loss of p16 p... |
PMC2359985_fig2_20987.jpg | Describe the main subject of this image. | Histological features of PAC120, HID25 and HID28 xenografts (HES staining, × 200 magnification). Left panels, untreated tumours; middle panels, docetaxel-treated tumours; right panels, docetaxel plus trastuzumab-treated tumours. (A) PAC120 tumours were characterised by a Gleason score of 9 (5+4) with compact sheets of ... |
PMC2359985_fig2_20986.jpg | What key item or scene is captured in this photo? | Histological features of PAC120, HID25 and HID28 xenografts (HES staining, × 200 magnification). Left panels, untreated tumours; middle panels, docetaxel-treated tumours; right panels, docetaxel plus trastuzumab-treated tumours. (A) PAC120 tumours were characterised by a Gleason score of 9 (5+4) with compact sheets of ... |
PMC2359985_fig2_20982.jpg | What is the main focus of this visual representation? | Histological features of PAC120, HID25 and HID28 xenografts (HES staining, × 200 magnification). Left panels, untreated tumours; middle panels, docetaxel-treated tumours; right panels, docetaxel plus trastuzumab-treated tumours. (A) PAC120 tumours were characterised by a Gleason score of 9 (5+4) with compact sheets of ... |
PMC2359985_fig2_20985.jpg | What does this image primarily show? | Histological features of PAC120, HID25 and HID28 xenografts (HES staining, × 200 magnification). Left panels, untreated tumours; middle panels, docetaxel-treated tumours; right panels, docetaxel plus trastuzumab-treated tumours. (A) PAC120 tumours were characterised by a Gleason score of 9 (5+4) with compact sheets of ... |
PMC2359985_fig2_20981.jpg | What is the focal point of this photograph? | Histological features of PAC120, HID25 and HID28 xenografts (HES staining, × 200 magnification). Left panels, untreated tumours; middle panels, docetaxel-treated tumours; right panels, docetaxel plus trastuzumab-treated tumours. (A) PAC120 tumours were characterised by a Gleason score of 9 (5+4) with compact sheets of ... |
PMC2359985_fig2_20989.jpg | What does this image primarily show? | Histological features of PAC120, HID25 and HID28 xenografts (HES staining, × 200 magnification). Left panels, untreated tumours; middle panels, docetaxel-treated tumours; right panels, docetaxel plus trastuzumab-treated tumours. (A) PAC120 tumours were characterised by a Gleason score of 9 (5+4) with compact sheets of ... |
PMC2359985_fig3_20975.jpg | What stands out most in this visual? | Expression pattern of HER2 and HSP90 in HID28 xenografts by immunohistochemistry. Left two panels, untreated tumours; middle two panels, docetaxel-treated tumours at day 3; right two panels, docetaxel/trastuzumab treatment (× 200 magnification). HER2 immunodetection. (A) The anti-HER2 antibody staining is weak, diffuse... |
PMC2359985_fig3_20976.jpg | What is shown in this image? | Expression pattern of HER2 and HSP90 in HID28 xenografts by immunohistochemistry. Left two panels, untreated tumours; middle two panels, docetaxel-treated tumours at day 3; right two panels, docetaxel/trastuzumab treatment (× 200 magnification). HER2 immunodetection. (A) The anti-HER2 antibody staining is weak, diffuse... |
PMC2359985_fig3_20979.jpg | What is being portrayed in this visual content? | Expression pattern of HER2 and HSP90 in HID28 xenografts by immunohistochemistry. Left two panels, untreated tumours; middle two panels, docetaxel-treated tumours at day 3; right two panels, docetaxel/trastuzumab treatment (× 200 magnification). HER2 immunodetection. (A) The anti-HER2 antibody staining is weak, diffuse... |
PMC2359985_fig3_20977.jpg | What is the dominant medical problem in this image? | Expression pattern of HER2 and HSP90 in HID28 xenografts by immunohistochemistry. Left two panels, untreated tumours; middle two panels, docetaxel-treated tumours at day 3; right two panels, docetaxel/trastuzumab treatment (× 200 magnification). HER2 immunodetection. (A) The anti-HER2 antibody staining is weak, diffuse... |
PMC2359985_fig3_20980.jpg | What does this image primarily show? | Expression pattern of HER2 and HSP90 in HID28 xenografts by immunohistochemistry. Left two panels, untreated tumours; middle two panels, docetaxel-treated tumours at day 3; right two panels, docetaxel/trastuzumab treatment (× 200 magnification). HER2 immunodetection. (A) The anti-HER2 antibody staining is weak, diffuse... |
PMC2359996_fig1_20991.jpg | What is the central feature of this picture? | Immunohistochemical staining of tissue factor in ovarian carcinoma tissues. (A) Negative control, (−); (B) weakly positive (<50% positive tumour cells), (+); (C) moderately positive (⩾50% positive tumour cells with weak intensity), (++); (D) strongly positive (⩾50% positive tumour cells with strong intensity), (+++), b... |
PMC2359996_fig1_20993.jpg | Describe the main subject of this image. | Immunohistochemical staining of tissue factor in ovarian carcinoma tissues. (A) Negative control, (−); (B) weakly positive (<50% positive tumour cells), (+); (C) moderately positive (⩾50% positive tumour cells with weak intensity), (++); (D) strongly positive (⩾50% positive tumour cells with strong intensity), (+++), b... |
PMC2359996_fig1_20992.jpg | What is the focal point of this photograph? | Immunohistochemical staining of tissue factor in ovarian carcinoma tissues. (A) Negative control, (−); (B) weakly positive (<50% positive tumour cells), (+); (C) moderately positive (⩾50% positive tumour cells with weak intensity), (++); (D) strongly positive (⩾50% positive tumour cells with strong intensity), (+++), b... |
PMC2359996_fig1_20990.jpg | What's the most prominent thing you notice in this picture? | Immunohistochemical staining of tissue factor in ovarian carcinoma tissues. (A) Negative control, (−); (B) weakly positive (<50% positive tumour cells), (+); (C) moderately positive (⩾50% positive tumour cells with weak intensity), (++); (D) strongly positive (⩾50% positive tumour cells with strong intensity), (+++), b... |
PMC2360001_fig1_20997.jpg | What object or scene is depicted here? | The pretreatment biopsy specimen (A–C) and the resected tumour (D) from a representative gastric cancer, which responded to neoadjuvant S-1/cisplatin chemotherapy. (A, D): HE staining, (B): TS immunoreactivity, (C): p53 immunoreactivity. Chemotherapy-induced histological changes including the disintegration of glandula... |
PMC2360001_fig1_20996.jpg | What stands out most in this visual? | The pretreatment biopsy specimen (A–C) and the resected tumour (D) from a representative gastric cancer, which responded to neoadjuvant S-1/cisplatin chemotherapy. (A, D): HE staining, (B): TS immunoreactivity, (C): p53 immunoreactivity. Chemotherapy-induced histological changes including the disintegration of glandula... |
PMC2360001_fig1_20995.jpg | What can you see in this picture? | The pretreatment biopsy specimen (A–C) and the resected tumour (D) from a representative gastric cancer, which responded to neoadjuvant S-1/cisplatin chemotherapy. (A, D): HE staining, (B): TS immunoreactivity, (C): p53 immunoreactivity. Chemotherapy-induced histological changes including the disintegration of glandula... |
PMC2360001_fig1_20994.jpg | What object or scene is depicted here? | The pretreatment biopsy specimen (A–C) and the resected tumour (D) from a representative gastric cancer, which responded to neoadjuvant S-1/cisplatin chemotherapy. (A, D): HE staining, (B): TS immunoreactivity, (C): p53 immunoreactivity. Chemotherapy-induced histological changes including the disintegration of glandula... |
PMC2360014_fig1_21004.jpg | What is the central feature of this picture? | Immunoreactivity of Twist observed in EOCs. (A–G) Positive expression of Twist in EOCs. (A, B) Endometrioid cystadenocarcinoma, (C, D) mucinous cystadenocarcinoma, (E, F) serous cystadenocarcinoma, (G) clear cell adenocarcinoma, (H) negative expression of Twist (clear cell adenocarcinoma); magnification × 100. |
PMC2360014_fig1_20998.jpg | What is shown in this image? | Immunoreactivity of Twist observed in EOCs. (A–G) Positive expression of Twist in EOCs. (A, B) Endometrioid cystadenocarcinoma, (C, D) mucinous cystadenocarcinoma, (E, F) serous cystadenocarcinoma, (G) clear cell adenocarcinoma, (H) negative expression of Twist (clear cell adenocarcinoma); magnification × 100. |
PMC2360014_fig1_21003.jpg | What is the dominant medical problem in this image? | Immunoreactivity of Twist observed in EOCs. (A–G) Positive expression of Twist in EOCs. (A, B) Endometrioid cystadenocarcinoma, (C, D) mucinous cystadenocarcinoma, (E, F) serous cystadenocarcinoma, (G) clear cell adenocarcinoma, (H) negative expression of Twist (clear cell adenocarcinoma); magnification × 100. |
PMC2360014_fig1_21001.jpg | Can you identify the primary element in this image? | Immunoreactivity of Twist observed in EOCs. (A–G) Positive expression of Twist in EOCs. (A, B) Endometrioid cystadenocarcinoma, (C, D) mucinous cystadenocarcinoma, (E, F) serous cystadenocarcinoma, (G) clear cell adenocarcinoma, (H) negative expression of Twist (clear cell adenocarcinoma); magnification × 100. |
PMC2360014_fig1_20999.jpg | What object or scene is depicted here? | Immunoreactivity of Twist observed in EOCs. (A–G) Positive expression of Twist in EOCs. (A, B) Endometrioid cystadenocarcinoma, (C, D) mucinous cystadenocarcinoma, (E, F) serous cystadenocarcinoma, (G) clear cell adenocarcinoma, (H) negative expression of Twist (clear cell adenocarcinoma); magnification × 100. |
PMC2360014_fig1_21002.jpg | What is the core subject represented in this visual? | Immunoreactivity of Twist observed in EOCs. (A–G) Positive expression of Twist in EOCs. (A, B) Endometrioid cystadenocarcinoma, (C, D) mucinous cystadenocarcinoma, (E, F) serous cystadenocarcinoma, (G) clear cell adenocarcinoma, (H) negative expression of Twist (clear cell adenocarcinoma); magnification × 100. |
PMC2360042_fig3_21008.jpg | What object or scene is depicted here? | CT scans of the patient who showed sustained PR during the trial: At baseline (A), day 84 (B), 12 (C) and 36 (D) months post-treatment. Resolution of one liver metastasis is evident by day 84 with significant ablation of the second, which also eventually resolves. The patient is a long-term survivor at ++36 months and ... |
PMC2360042_fig3_21009.jpg | What object or scene is depicted here? | CT scans of the patient who showed sustained PR during the trial: At baseline (A), day 84 (B), 12 (C) and 36 (D) months post-treatment. Resolution of one liver metastasis is evident by day 84 with significant ablation of the second, which also eventually resolves. The patient is a long-term survivor at ++36 months and ... |
PMC2360042_fig3_21007.jpg | Describe the main subject of this image. | CT scans of the patient who showed sustained PR during the trial: At baseline (A), day 84 (B), 12 (C) and 36 (D) months post-treatment. Resolution of one liver metastasis is evident by day 84 with significant ablation of the second, which also eventually resolves. The patient is a long-term survivor at ++36 months and ... |
PMC2360042_fig3_21006.jpg | What is the main focus of this visual representation? | CT scans of the patient who showed sustained PR during the trial: At baseline (A), day 84 (B), 12 (C) and 36 (D) months post-treatment. Resolution of one liver metastasis is evident by day 84 with significant ablation of the second, which also eventually resolves. The patient is a long-term survivor at ++36 months and ... |
PMC2360051_fig1_21010.jpg | What is the core subject represented in this visual? | Immunohistochemical analysis of the expressions of phenotypic markers in gastric carcinoma. (A) Human gastric mucin (HGM) expressed in the cancer cell cytoplasm (45M1, original magnification × 200). (B) MUC6 glycoprotein expressed in the cancer cell cytoplasm (CLH5, original magnification × 100). (C) MUC2 glycoprotein ... |
PMC2360051_fig1_21012.jpg | What stands out most in this visual? | Immunohistochemical analysis of the expressions of phenotypic markers in gastric carcinoma. (A) Human gastric mucin (HGM) expressed in the cancer cell cytoplasm (45M1, original magnification × 200). (B) MUC6 glycoprotein expressed in the cancer cell cytoplasm (CLH5, original magnification × 100). (C) MUC2 glycoprotein ... |
PMC2360051_fig1_21011.jpg | What is the dominant medical problem in this image? | Immunohistochemical analysis of the expressions of phenotypic markers in gastric carcinoma. (A) Human gastric mucin (HGM) expressed in the cancer cell cytoplasm (45M1, original magnification × 200). (B) MUC6 glycoprotein expressed in the cancer cell cytoplasm (CLH5, original magnification × 100). (C) MUC2 glycoprotein ... |
PMC2360051_fig1_21013.jpg | What is the dominant medical problem in this image? | Immunohistochemical analysis of the expressions of phenotypic markers in gastric carcinoma. (A) Human gastric mucin (HGM) expressed in the cancer cell cytoplasm (45M1, original magnification × 200). (B) MUC6 glycoprotein expressed in the cancer cell cytoplasm (CLH5, original magnification × 100). (C) MUC2 glycoprotein ... |
PMC2360069_fig1_21014.jpg | What object or scene is depicted here? | Representative examples of PTK6 IHC (objective magnification × 40) in normal breast epithelium (A), and in breast carcinomas classified as 1+ (B), 2+ (C), and 3+ (D). |
PMC2360069_fig1_21017.jpg | What is the focal point of this photograph? | Representative examples of PTK6 IHC (objective magnification × 40) in normal breast epithelium (A), and in breast carcinomas classified as 1+ (B), 2+ (C), and 3+ (D). |
PMC2360069_fig1_21015.jpg | What is the central feature of this picture? | Representative examples of PTK6 IHC (objective magnification × 40) in normal breast epithelium (A), and in breast carcinomas classified as 1+ (B), 2+ (C), and 3+ (D). |
PMC2360077_fig3_21021.jpg | What is the main focus of this visual representation? | Results of kinetic modelling of DCE-MRI data. (A) Example of parametric maps of the permeability surface product (PS) in control animals and rhEPO-treated animals before and after RT. The tumour is masked and the arrow points to the pixel containing the selected vascular input function. (B–D) Combined kinetic data for ... |
PMC2360077_fig3_21025.jpg | Can you identify the primary element in this image? | Results of kinetic modelling of DCE-MRI data. (A) Example of parametric maps of the permeability surface product (PS) in control animals and rhEPO-treated animals before and after RT. The tumour is masked and the arrow points to the pixel containing the selected vascular input function. (B–D) Combined kinetic data for ... |
PMC2360077_fig3_21024.jpg | Describe the main subject of this image. | Results of kinetic modelling of DCE-MRI data. (A) Example of parametric maps of the permeability surface product (PS) in control animals and rhEPO-treated animals before and after RT. The tumour is masked and the arrow points to the pixel containing the selected vascular input function. (B–D) Combined kinetic data for ... |
PMC2360077_fig3_21023.jpg | What is the core subject represented in this visual? | Results of kinetic modelling of DCE-MRI data. (A) Example of parametric maps of the permeability surface product (PS) in control animals and rhEPO-treated animals before and after RT. The tumour is masked and the arrow points to the pixel containing the selected vascular input function. (B–D) Combined kinetic data for ... |
PMC2360090_fig2_21030.jpg | What is the dominant medical problem in this image? | Cyclin D1 expression in metastatic prostate carcinoma. Representative immunohistochemical images from prostate-derived lymph node metastatic tumours. Left panel: Haematoxylin and eosin staining showing disorganised architecture of the metastatic tumours. Middle panel: Strong nuclear positive AR staining in the majority... |
PMC2360109_fig2_21034.jpg | What object or scene is depicted here? | Patterns of leucocyte infiltration in adenocarcinoma lesions (PAC), adjacent benign tissue (peri-PAC) and specimens of nodular hyperplasia of the prostate gland (NHPG). (A) Tissue infiltrating leucocytes in PAC, peri-PAC and NHPG identified according to CD45 immune reactivity (magnification × 40). (B) Percentages of ti... |
PMC2360109_fig2_21033.jpg | What does this image primarily show? | Patterns of leucocyte infiltration in adenocarcinoma lesions (PAC), adjacent benign tissue (peri-PAC) and specimens of nodular hyperplasia of the prostate gland (NHPG). (A) Tissue infiltrating leucocytes in PAC, peri-PAC and NHPG identified according to CD45 immune reactivity (magnification × 40). (B) Percentages of ti... |
PMC2360109_fig2_21032.jpg | What can you see in this picture? | Patterns of leucocyte infiltration in adenocarcinoma lesions (PAC), adjacent benign tissue (peri-PAC) and specimens of nodular hyperplasia of the prostate gland (NHPG). (A) Tissue infiltrating leucocytes in PAC, peri-PAC and NHPG identified according to CD45 immune reactivity (magnification × 40). (B) Percentages of ti... |
PMC2360109_fig3_21049.jpg | What's the most prominent thing you notice in this picture? | Composition of clustered infiltrates in adenocarcinoma lesions (PAC), adjacent benign tissue (peri-PAC) and specimens of nodular hyperplasia of the prostate gland (NHPG). Successive tissue sections were reacted to antibodies recognising common (CD45) and subset-specific (CD3, CD4, CD8 – T lymphocytes, CD20 – B lymphocy... |
PMC2360109_fig3_21044.jpg | What is being portrayed in this visual content? | Composition of clustered infiltrates in adenocarcinoma lesions (PAC), adjacent benign tissue (peri-PAC) and specimens of nodular hyperplasia of the prostate gland (NHPG). Successive tissue sections were reacted to antibodies recognising common (CD45) and subset-specific (CD3, CD4, CD8 – T lymphocytes, CD20 – B lymphocy... |
PMC2360109_fig3_21045.jpg | What is the focal point of this photograph? | Composition of clustered infiltrates in adenocarcinoma lesions (PAC), adjacent benign tissue (peri-PAC) and specimens of nodular hyperplasia of the prostate gland (NHPG). Successive tissue sections were reacted to antibodies recognising common (CD45) and subset-specific (CD3, CD4, CD8 – T lymphocytes, CD20 – B lymphocy... |
PMC2360109_fig3_21054.jpg | What is the principal component of this image? | Composition of clustered infiltrates in adenocarcinoma lesions (PAC), adjacent benign tissue (peri-PAC) and specimens of nodular hyperplasia of the prostate gland (NHPG). Successive tissue sections were reacted to antibodies recognising common (CD45) and subset-specific (CD3, CD4, CD8 – T lymphocytes, CD20 – B lymphocy... |
PMC2360109_fig3_21048.jpg | What is the principal component of this image? | Composition of clustered infiltrates in adenocarcinoma lesions (PAC), adjacent benign tissue (peri-PAC) and specimens of nodular hyperplasia of the prostate gland (NHPG). Successive tissue sections were reacted to antibodies recognising common (CD45) and subset-specific (CD3, CD4, CD8 – T lymphocytes, CD20 – B lymphocy... |
PMC2360109_fig3_21051.jpg | What is the core subject represented in this visual? | Composition of clustered infiltrates in adenocarcinoma lesions (PAC), adjacent benign tissue (peri-PAC) and specimens of nodular hyperplasia of the prostate gland (NHPG). Successive tissue sections were reacted to antibodies recognising common (CD45) and subset-specific (CD3, CD4, CD8 – T lymphocytes, CD20 – B lymphocy... |
PMC2360109_fig3_21052.jpg | What is the principal component of this image? | Composition of clustered infiltrates in adenocarcinoma lesions (PAC), adjacent benign tissue (peri-PAC) and specimens of nodular hyperplasia of the prostate gland (NHPG). Successive tissue sections were reacted to antibodies recognising common (CD45) and subset-specific (CD3, CD4, CD8 – T lymphocytes, CD20 – B lymphocy... |
PMC2360109_fig3_21056.jpg | What is being portrayed in this visual content? | Composition of clustered infiltrates in adenocarcinoma lesions (PAC), adjacent benign tissue (peri-PAC) and specimens of nodular hyperplasia of the prostate gland (NHPG). Successive tissue sections were reacted to antibodies recognising common (CD45) and subset-specific (CD3, CD4, CD8 – T lymphocytes, CD20 – B lymphocy... |
PMC2360109_fig3_21053.jpg | What is the dominant medical problem in this image? | Composition of clustered infiltrates in adenocarcinoma lesions (PAC), adjacent benign tissue (peri-PAC) and specimens of nodular hyperplasia of the prostate gland (NHPG). Successive tissue sections were reacted to antibodies recognising common (CD45) and subset-specific (CD3, CD4, CD8 – T lymphocytes, CD20 – B lymphocy... |
PMC2360109_fig3_21042.jpg | What object or scene is depicted here? | Composition of clustered infiltrates in adenocarcinoma lesions (PAC), adjacent benign tissue (peri-PAC) and specimens of nodular hyperplasia of the prostate gland (NHPG). Successive tissue sections were reacted to antibodies recognising common (CD45) and subset-specific (CD3, CD4, CD8 – T lymphocytes, CD20 – B lymphocy... |
PMC2360109_fig3_21046.jpg | What can you see in this picture? | Composition of clustered infiltrates in adenocarcinoma lesions (PAC), adjacent benign tissue (peri-PAC) and specimens of nodular hyperplasia of the prostate gland (NHPG). Successive tissue sections were reacted to antibodies recognising common (CD45) and subset-specific (CD3, CD4, CD8 – T lymphocytes, CD20 – B lymphocy... |
PMC2360109_fig4_21038.jpg | What is the principal component of this image? | Expression of IL-10 in adenocarcinoma lesions (PAC), adjacent benign tissue (peri-PAC) and specimens of nodular hyperplasia of the prostate gland (NHPG). (A) Typical pattern of IL-10 expression in malignant and benign prostate tissue (magnification × 200). (B) Percentages of IL-10-expressing specimens. |
PMC2360109_fig4_21037.jpg | What is being portrayed in this visual content? | Expression of IL-10 in adenocarcinoma lesions (PAC), adjacent benign tissue (peri-PAC) and specimens of nodular hyperplasia of the prostate gland (NHPG). (A) Typical pattern of IL-10 expression in malignant and benign prostate tissue (magnification × 200). (B) Percentages of IL-10-expressing specimens. |
PMC2360109_fig4_21039.jpg | What is the central feature of this picture? | Expression of IL-10 in adenocarcinoma lesions (PAC), adjacent benign tissue (peri-PAC) and specimens of nodular hyperplasia of the prostate gland (NHPG). (A) Typical pattern of IL-10 expression in malignant and benign prostate tissue (magnification × 200). (B) Percentages of IL-10-expressing specimens. |
PMC2360118_fig3_21061.jpg | Describe the main subject of this image. | Preoperative CT scan showing a polypoid tumour of the descending colon extending into the lumen (black arrowheads). Tumour does not extend beyond the contour of the muscle coat indicating that this is an early T1/T2 tumour. Pathological staging was pT2. |
PMC2360118_fig4_21059.jpg | Describe the main subject of this image. | Preoperative CT scan showing a fungating tumour of the ascending colon. The colonic wall is thickened and the posterior contour is irregular owing to tumour projection beyond the non-peritonealised muscle coat. As there is no tumour involvement of the peritonealised surfaces, this is considered a relatively good progno... |
PMC2360118_fig4_21060.jpg | What can you see in this picture? | Preoperative CT scan showing a fungating tumour of the ascending colon. The colonic wall is thickened and the posterior contour is irregular owing to tumour projection beyond the non-peritonealised muscle coat. As there is no tumour involvement of the peritonealised surfaces, this is considered a relatively good progno... |
PMC2360118_fig6_21057.jpg | What stands out most in this visual? | Preoperative CT scan showing a bulky tumour of the descending/sigmoid junction. There is irregular nodular extension medially (arrows) indicating T3 infiltration. This is likely to extend through the medial nonperitonealised, mesenteric surface of the colon. The pathological stage was confirmed as pT3. |
PMC2360169_fig2_21067.jpg | What is the core subject represented in this visual? | Electron micrographs of different types of nanoparticles. (A) Fe nanoparticles coated with poly(N-vinyl-2-pyrrolidone), which stabilises the nanoparticles. (B) TEM image of Au nanoparticles, (∼6 nm), which are being harnessed for sensing protein markers. The aggregation of these nanoparticles is visualised from a chang... |
PMC2360169_fig2_21065.jpg | What key item or scene is captured in this photo? | Electron micrographs of different types of nanoparticles. (A) Fe nanoparticles coated with poly(N-vinyl-2-pyrrolidone), which stabilises the nanoparticles. (B) TEM image of Au nanoparticles, (∼6 nm), which are being harnessed for sensing protein markers. The aggregation of these nanoparticles is visualised from a chang... |
PMC2360169_fig2_21062.jpg | What object or scene is depicted here? | Electron micrographs of different types of nanoparticles. (A) Fe nanoparticles coated with poly(N-vinyl-2-pyrrolidone), which stabilises the nanoparticles. (B) TEM image of Au nanoparticles, (∼6 nm), which are being harnessed for sensing protein markers. The aggregation of these nanoparticles is visualised from a chang... |
PMC2360169_fig2_21063.jpg | Describe the main subject of this image. | Electron micrographs of different types of nanoparticles. (A) Fe nanoparticles coated with poly(N-vinyl-2-pyrrolidone), which stabilises the nanoparticles. (B) TEM image of Au nanoparticles, (∼6 nm), which are being harnessed for sensing protein markers. The aggregation of these nanoparticles is visualised from a chang... |
PMC2360206_fig1_21071.jpg | What is the main focus of this visual representation? | Functional renal perfusion imaging by MAG3 nuclear scanning, performed pretreatment (A) and post-treatment on days 3 (B) and 14 (C), in a patient who experienced a reversible decline in renal function when treated with seliciclib at 1600 mg day−1. Baseline pre-treatment renogram (A) shows slight asymmetry in renal func... |
PMC2360206_fig1_21069.jpg | What can you see in this picture? | Functional renal perfusion imaging by MAG3 nuclear scanning, performed pretreatment (A) and post-treatment on days 3 (B) and 14 (C), in a patient who experienced a reversible decline in renal function when treated with seliciclib at 1600 mg day−1. Baseline pre-treatment renogram (A) shows slight asymmetry in renal func... |
PMC2360224_fig1_21075.jpg | What is the central feature of this picture? | Carbonic anhydrase IX immunohistochemistry. (A) Weak focal staining. Some tumour cells are unstained (single arrow), while others show weak CA IX staining of cell membranes (block arrow) (magnification × 20). (B) Weak diffuse staining. All tumour cells show CA IX staining but the intensity is weak (× 20). (C) Strong fo... |
PMC2360224_fig1_21073.jpg | Can you identify the primary element in this image? | Carbonic anhydrase IX immunohistochemistry. (A) Weak focal staining. Some tumour cells are unstained (single arrow), while others show weak CA IX staining of cell membranes (block arrow) (magnification × 20). (B) Weak diffuse staining. All tumour cells show CA IX staining but the intensity is weak (× 20). (C) Strong fo... |
PMC2360224_fig1_21074.jpg | What is being portrayed in this visual content? | Carbonic anhydrase IX immunohistochemistry. (A) Weak focal staining. Some tumour cells are unstained (single arrow), while others show weak CA IX staining of cell membranes (block arrow) (magnification × 20). (B) Weak diffuse staining. All tumour cells show CA IX staining but the intensity is weak (× 20). (C) Strong fo... |
PMC2360224_fig1_21077.jpg | Describe the main subject of this image. | Carbonic anhydrase IX immunohistochemistry. (A) Weak focal staining. Some tumour cells are unstained (single arrow), while others show weak CA IX staining of cell membranes (block arrow) (magnification × 20). (B) Weak diffuse staining. All tumour cells show CA IX staining but the intensity is weak (× 20). (C) Strong fo... |
PMC2360224_fig1_21076.jpg | Can you identify the primary element in this image? | Carbonic anhydrase IX immunohistochemistry. (A) Weak focal staining. Some tumour cells are unstained (single arrow), while others show weak CA IX staining of cell membranes (block arrow) (magnification × 20). (B) Weak diffuse staining. All tumour cells show CA IX staining but the intensity is weak (× 20). (C) Strong fo... |
PMC2360231_fig1_21078.jpg | What key item or scene is captured in this photo? | (A, B) Immunohistochemistry of HSP27 showing equal staining intensity in the primary lesion (A) and the liver metastasis (B), since the gene expression was as well equal in the array ( × 200 magnification). |
PMC2360231_fig1_21079.jpg | What is shown in this image? | (A, B) Immunohistochemistry of HSP27 showing equal staining intensity in the primary lesion (A) and the liver metastasis (B), since the gene expression was as well equal in the array ( × 200 magnification). |
PMC2360231_fig2_21081.jpg | What is the dominant medical problem in this image? | (A, B) Immunohistochemistry of BNIP3L of the primary tumour (A) and of the liver metastasis (B) with a weaker staining ( × 200 magnification). |
PMC2360231_fig3_21083.jpg | What is the dominant medical problem in this image? | (A and B) Immunohistochemistry of PTPN14 with a strong staining in the primary lesions (A) compared with a weak staining in the liver metastasis reflecting equal array results ( × 200 magnification). |
PMC2360231_fig3_21082.jpg | What is the dominant medical problem in this image? | (A and B) Immunohistochemistry of PTPN14 with a strong staining in the primary lesions (A) compared with a weak staining in the liver metastasis reflecting equal array results ( × 200 magnification). |
PMC2360243_fig1_21084.jpg | What is the core subject represented in this visual? | Angiogenesis scoring. (A) Tubule lengths (l) and number of branch points (bp). (B) Endothelial cell (EC) surface area (a). Relative angiogenesis score (s)=bp × l × a. Photographs were imaged at a magnification of × 100. |
PMC2360243_fig1_21085.jpg | What is the core subject represented in this visual? | Angiogenesis scoring. (A) Tubule lengths (l) and number of branch points (bp). (B) Endothelial cell (EC) surface area (a). Relative angiogenesis score (s)=bp × l × a. Photographs were imaged at a magnification of × 100. |
PMC2360248_fig2_21088.jpg | What is the principal component of this image? | Immunohistochemical staining patterns for GnT-V and staining of L4-PHA in endometrial cancers. Staining pattern of a tumour: (A) GnT-V low; (B and C) GnT-V high. (D–F) L4-PHA staining and (G–I) PCNA immunostaining were performed simultaneously with the same A, B, and C specimens, respectively. (J) Normal endometrial ce... |
PMC2360248_fig2_21086.jpg | Can you identify the primary element in this image? | Immunohistochemical staining patterns for GnT-V and staining of L4-PHA in endometrial cancers. Staining pattern of a tumour: (A) GnT-V low; (B and C) GnT-V high. (D–F) L4-PHA staining and (G–I) PCNA immunostaining were performed simultaneously with the same A, B, and C specimens, respectively. (J) Normal endometrial ce... |
PMC2360248_fig2_21095.jpg | What is the core subject represented in this visual? | Immunohistochemical staining patterns for GnT-V and staining of L4-PHA in endometrial cancers. Staining pattern of a tumour: (A) GnT-V low; (B and C) GnT-V high. (D–F) L4-PHA staining and (G–I) PCNA immunostaining were performed simultaneously with the same A, B, and C specimens, respectively. (J) Normal endometrial ce... |
PMC2360248_fig2_21094.jpg | What is being portrayed in this visual content? | Immunohistochemical staining patterns for GnT-V and staining of L4-PHA in endometrial cancers. Staining pattern of a tumour: (A) GnT-V low; (B and C) GnT-V high. (D–F) L4-PHA staining and (G–I) PCNA immunostaining were performed simultaneously with the same A, B, and C specimens, respectively. (J) Normal endometrial ce... |
PMC2360248_fig2_21092.jpg | What's the most prominent thing you notice in this picture? | Immunohistochemical staining patterns for GnT-V and staining of L4-PHA in endometrial cancers. Staining pattern of a tumour: (A) GnT-V low; (B and C) GnT-V high. (D–F) L4-PHA staining and (G–I) PCNA immunostaining were performed simultaneously with the same A, B, and C specimens, respectively. (J) Normal endometrial ce... |
PMC2360248_fig2_21096.jpg | What stands out most in this visual? | Immunohistochemical staining patterns for GnT-V and staining of L4-PHA in endometrial cancers. Staining pattern of a tumour: (A) GnT-V low; (B and C) GnT-V high. (D–F) L4-PHA staining and (G–I) PCNA immunostaining were performed simultaneously with the same A, B, and C specimens, respectively. (J) Normal endometrial ce... |
PMC2360248_fig2_21087.jpg | What object or scene is depicted here? | Immunohistochemical staining patterns for GnT-V and staining of L4-PHA in endometrial cancers. Staining pattern of a tumour: (A) GnT-V low; (B and C) GnT-V high. (D–F) L4-PHA staining and (G–I) PCNA immunostaining were performed simultaneously with the same A, B, and C specimens, respectively. (J) Normal endometrial ce... |
PMC2360248_fig2_21093.jpg | What is the principal component of this image? | Immunohistochemical staining patterns for GnT-V and staining of L4-PHA in endometrial cancers. Staining pattern of a tumour: (A) GnT-V low; (B and C) GnT-V high. (D–F) L4-PHA staining and (G–I) PCNA immunostaining were performed simultaneously with the same A, B, and C specimens, respectively. (J) Normal endometrial ce... |
PMC2360248_fig2_21091.jpg | What is being portrayed in this visual content? | Immunohistochemical staining patterns for GnT-V and staining of L4-PHA in endometrial cancers. Staining pattern of a tumour: (A) GnT-V low; (B and C) GnT-V high. (D–F) L4-PHA staining and (G–I) PCNA immunostaining were performed simultaneously with the same A, B, and C specimens, respectively. (J) Normal endometrial ce... |
PMC2360248_fig2_21090.jpg | Can you identify the primary element in this image? | Immunohistochemical staining patterns for GnT-V and staining of L4-PHA in endometrial cancers. Staining pattern of a tumour: (A) GnT-V low; (B and C) GnT-V high. (D–F) L4-PHA staining and (G–I) PCNA immunostaining were performed simultaneously with the same A, B, and C specimens, respectively. (J) Normal endometrial ce... |
PMC2360248_fig2_21097.jpg | What does this image primarily show? | Immunohistochemical staining patterns for GnT-V and staining of L4-PHA in endometrial cancers. Staining pattern of a tumour: (A) GnT-V low; (B and C) GnT-V high. (D–F) L4-PHA staining and (G–I) PCNA immunostaining were performed simultaneously with the same A, B, and C specimens, respectively. (J) Normal endometrial ce... |
PMC2360248_fig2_21089.jpg | What is the focal point of this photograph? | Immunohistochemical staining patterns for GnT-V and staining of L4-PHA in endometrial cancers. Staining pattern of a tumour: (A) GnT-V low; (B and C) GnT-V high. (D–F) L4-PHA staining and (G–I) PCNA immunostaining were performed simultaneously with the same A, B, and C specimens, respectively. (J) Normal endometrial ce... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.